These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 20675359

  • 1. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
    Valerio CJ, Handler CE, Kabunga P, Smith CJ, Denton CP, Coghlan JG.
    Rheumatology (Oxford); 2010 Nov; 49(11):2147-53. PubMed ID: 20675359
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
    Faruqi S, Fathi H, Morice AH.
    Int J Cardiol; 2010 Oct 29; 144(3):e43-5. PubMed ID: 19171388
    [Abstract] [Full Text] [Related]

  • 6. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P, Strange G, Wlodarczyk J, Dalton B, Stewart S, Gabbay E, Keogh A.
    BMC Cardiovasc Disord; 2010 Feb 22; 10():9. PubMed ID: 20170553
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
    Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ.
    Ann Rheum Dis; 2007 Nov 22; 66(11):1467-72. PubMed ID: 17472992
    [Abstract] [Full Text] [Related]

  • 10. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
    Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N, STRIDE-2 Study Group.
    J Am Coll Cardiol; 2006 May 16; 47(10):2049-56. PubMed ID: 16697324
    [Abstract] [Full Text] [Related]

  • 11. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
    Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin LJ.
    Int J Cardiol; 2014 Mar 15; 172(2):332-9. PubMed ID: 24525158
    [Abstract] [Full Text] [Related]

  • 12. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ.
    J Heart Lung Transplant; 2007 Jan 15; 26(1):63-9. PubMed ID: 17234519
    [Abstract] [Full Text] [Related]

  • 13. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, Crescenzi E, Nona A, Benedetti G, Ferrante F, Sciomer S, Fedele F.
    Regul Pept; 2008 Nov 29; 151(1-3):48-53. PubMed ID: 18796317
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
    Cacoub P, Amoura Z, Langleben D.
    Rev Med Interne; 2008 Apr 29; 29(4):283-9. PubMed ID: 18243424
    [Abstract] [Full Text] [Related]

  • 15. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B, Langleben D, Hirsch AM, Schlesinger RD, Eisenberg MJ, Joyal D, Blenkhorn F, Lesenko L.
    Can J Cardiol; 2013 Jun 29; 29(6):672-7. PubMed ID: 22819360
    [Abstract] [Full Text] [Related]

  • 16. Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations.
    Dhaun N, Vachiery JL, Benza RL, Naeije R, Hwang LJ, Liu X, Teal S, Webb DJ.
    J Heart Lung Transplant; 2014 May 29; 33(5):521-7. PubMed ID: 24656288
    [Abstract] [Full Text] [Related]

  • 17. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
    Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, Sfriso P, Iliceto S, Todesco S.
    Eur J Clin Invest; 2006 Sep 29; 36 Suppl 3():49-53. PubMed ID: 16919011
    [Abstract] [Full Text] [Related]

  • 18. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
    Stevenson MD, Macdonald FC, Langley J, Hunsche E, Akehurst R.
    Value Health; 2009 Sep 29; 12(8):1100-5. PubMed ID: 19558373
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.